Synthekine

Today, we announced the first patient has been dosed in SYNERGY-101, our global, randomized Phase 2 clinical trial evaluating STK-012 combined with pembrolizumab and chemotherapy (PCT) vs. PCT in first-line, PD-L1 negative nonsquamous #NSCLC. Learn more: synthekine.com/news/first-pat…

Thank you, @bradloncar, for connecting with our President and CEO, Debanjan Ray, at #SITC2025 to learn more about how we’re advancing the IL-2 field with our novel α/β IL-2 receptor biased partial agonist, STK-012. Watch the full interview here: bit.ly/47JW0LT

Today, we announced positive Ph 1a/1b data for STK-012 in combination with pembrolizumab + chemotherapy in first-line PD-L1–negative nonsquamous #NSCLC. Be sure to catch our late-breaking oral presentation tomorrow at #SITC2025 highlighting these results! synthekine.com/news/synthekin…

Next week, we’ll be presenting data at #SITC2025! Don’t miss our late-breaking oral presentation highlighting initial clinical data from our Phase 1a/1b study evaluating STK-012 in first-line, PD-L1 negative nonsquamous #NSCLC patients. synthekine.com/news/synthekin… @sitcancer

#DYK ~50M Americans are living with an autoimmune disease? At Synthekine, we’re advancing next-gen selective cytokine therapeutics with the potential to change the treatment paradigm for autoimmune diseases. Learn more: bit.ly/41IJMBt #AutoimmuneAwarenessMonth

We look forward to presenting at @KeystoneSymp conferences next week! Join us in Banff to learn more about our approaches to IL-2 in cancer immunotherapy and cell therapy: keystonesymposia.org/conferences/co… keystonesymposia.org/conferences/co… #KSCancerImmune25 #KSCellTherapy25

We look forward to presenting at @biocom's Global Life Science Partnering & Investor Conference. Join us as we discuss our latest advancements for #cancer, #autoimmune, and #inflammatory diseases. #BiocomGPIC

Yesterday at #ASH24, we presented positive initial results from our Phase 1 study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ hematologic malignancies. Learn more about our results: synthekine.com/news/synthekin… @ASH_hematology

#DYK Lung cancer is the most common cause of #cancer death in the United States? This Lung Cancer Awareness Month, join us in raising awareness, supporting ongoing research, and honoring the strength and resilience of those impacted by #LungCancer.  #LCAM2024

#ICYMI our CEO, Debanjan Ray, joined other past #Fierce15 honorees on stage at the @FierceBiotech Summit to share recent company progress & discuss the groundbreaking work shaping the future of #biotech. To explore collaboration opportunities, contact us at bd@synthekine.com

Our scientific founder, Dr. Christopher Garcia shared insights into how protein engineering is transforming the landscape of treatment for #cancer and #autoimmune diseases in a recent episode of the @timmermanreport’s The Long Run podcast. Listen here: timmermanreport.com/2024/10/engine…

Tomorrow, we will present preclinical data on STK-009 + SYNCAR-001, our orthogonal IL-2 & CD19 #CART investigational therapy, at the @ACRheum Convergence. These results demonstrate its potential to treat autoimmune diseases w/o requiring lymphodepletion. bit.ly/3UV3KoJ

Today, we presented positive translational data of our first-in-class α/β-IL-2R biased partial agonist, STK-012, and preclinical and GLP toxicology data on our biased IL-12 cytokine partial agonist, STK-026, at #SITC24. Learn more: synthekine.com/news/synthekin…

We look forward to presenting data from multiple abstracts at the 12th Annual Meeting of the @CytokineSociety (ICIS) jointly held with the Korean Association of Immunologists International Meeting this month! See our poster and presentation details below: #Cytokines2024 #KAI2024

Our CMO, Naiyer Rizvi, M.D., has co-authored a journal article published in @NatureMedicine! His insights have not only deepened our knowledge but also advanced the understanding of others in the field of #immunotherapy for #cancer treatment. nature.com/articles/s4159…

Join us at the #FierceBiotechSummit today, where our CEO, Debanjan Ray, will join other past #Fierce15 honorees to discuss recent company milestones and share insights, experiences and visions for the evolving #biotech landscape. bit.ly/3BoJ6qo @LifeSciEvents

Our CSO, Martin Oft, M.D., will be sharing key insights from our Phase 1 study of STK-012, our first-in-class α/β-biased IL-2 partial agonist for patients with advanced solid tumors, at “The Promise of Interleukin-2 Therapy Conference” in Paris, France: bit.ly/4fX4lz8

Today, we announced that the #FDA has granted Fast Track designation to SYNCAR-001 + STK-009, our CD19 #CART and orthogonal IL-2 investigational therapy, for the treatment of systemic #lupus erythematosus (#SLE), without the use of lymphodepletion: bit.ly/4ebQFhY

#DYK Lung cancer is the leading cause of cancer death in the United States, accounting for an estimated 1 in 5 of all cancer deaths? On #WorldLungCancerDay, join us as we raise awareness and support the countless individuals and families impacted by lung cancer. #WLCD2024

Alex Azrilevich, Pharm.D., our VP, Clinical Development, will be presenting on the promising potential of STK-012, our first-in-class α/β-biased IL-2 partial agonist for patients with advanced solid tumors, at #KCRS24. Learn more: bit.ly/45RjH3r